PPARγ ligands attenuate mesangial contractile dysfunction in high glucose

Kidney International

Volumn 65, Issue 3, 2004, Pages 961-971

  Ueta, Maki ^b   Wakisaka, Masanori ^a   Ago, Tetsuro ^b   Kitazono, Takanari ^b   Nakamura, Udai ^b   Yoshinari, Mototaka ^b   Iwase, Masanori ^b   Iida, Mitsuo ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b NONE

Author keywords

Contraction; Diabetic nephropathy; Mesangial cell; Phenotype; PPAR ; Thiazolidinediones

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ACETYLSALICYLIC ACID; ALPHA ACTIN; ANGIOTENSIN; COMPLEMENTARY DNA; GLUCOSE; INDOMETACIN; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN KINASE C; TUMOR NECROSIS FACTOR ALPHA; 15 DEOXYPROSTAGLANDIN J2; 15-DEOXYPROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ACTIN; ANGIOTENSIN II; ANTIDIABETIC AGENT; CELL RECEPTOR; DRUG DERIVATIVE; ENZYME INHIBITOR; FLAVONOID; PROSTAGLANDIN D2; PROSTAGLANDIN SYNTHASE INHIBITOR; TRANSCRIPTION FACTOR; VASOCONSTRICTOR AGENT;

ANIMAL CELL; ARTICLE; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; MESANGIUM CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE CONTRACTION; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION; GENETICS; MESANGIUM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ACTINS; ANGIOTENSIN II; ANIMALS; ASPIRIN; CELLS, CULTURED; CYCLOOXYGENASE INHIBITORS; DNA, ANTISENSE; ENZYME INHIBITORS; FLAVONOIDS; GENE EXPRESSION; GLOMERULAR MESANGIUM; GLUCOSE; HYPOGLYCEMIC AGENTS; INDOMETHACIN; LIGANDS; PROSTAGLANDIN D2; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; VASOCONSTRICTOR AGENTS;

EID: 1342343888     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00474.x     Document Type: Article

References (55)

1. ROSEN ED, SARRAF P, TROY AE, et al: PPARgamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4:611-617, 1999
2. TONTONOZ P, NAGY L, ALVARETZ JG, et al: PPARγ promotes monocyte/macrophage differentiation and uptake oxidized LDL. Cell 93:241-252, 1998
3. BARAK Y, NELSON MC, ONG ES, et al: PPARγ is required for placental, cardiac, and adipose tissue development. Mol Cell 4:585-595, 1999
4. ASANO T, WAKISAKA M, YOSHINARI M. et al: Peroxisome proliferator activated receptorγ1 (PPARγ1) expresses in rat mesangial cells and PPARγ agonists modulate its differentiation. Biochim Biophys Acta 1497:148-154, 2000
5. YOSHIMOTO T, NARUSE M, SHIZUME H, et al: Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 145:333-340, 1999
6. INABA T, ISHIBASHI S, HARADA K, et al: Synergistic effects of transforming growth factor-beta on the expression of c-fms, macrophage colony-stimulating factor receptor gene, in vascular smooth muscle cells. FEBS Lett 399:207-210, 1996
7. SCHWARZ SM: Perspectives series: Cell adhesion in vascular biology. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 99:2814-2816, 1997
8. Ross R: The pathogenesis of atherosclerosis: A perspective for 1990s. Nature 362:801-809, 1993
9. OSTERBY R: Structural changes in diabetic kidney. Clin Endocrine Metab 15:733-75, 1986
10. MAUER SM, STEFFES MW, CONNETT J, et al: The development of lesions in the glomerular basement membrane and mesangium after transplantation of normal kidneys to diabetic patients. Diabetes 32:948-952, 1983
11. LING BN, SEAL EE, EATON DC: Regulation of mesangial cell ion channels by insulin and angiotensin II. Possible role in diabetic glomerular hyperfiltration. J Clin Invest 92:2141-215, 1993
12. KREISBERG JI, VENKATACHALAM M, TROYER D: Contractile properties of cultured glomerular mesangial cells. Am J Physiol 249:F 457-463, 1985
13. 2+ independent. Diabetes 44:759-766, 1995
14. DERYLO B, BABAZONO T, GLOGOWSKI E. et al: High glucose-induced mesangial cell altered contractility: Role of the polyol pathway. Diabetlogia 41:507-515, 1998
15. MAKINO H, KASHIHARA N, SUGIYAMA H, et al: Phenotypic changes of the mesangium in diabetic nephropathy. J Diabetes Compl 9:282-284, 1995
16. MAKINO H, KASHIHARA N, SUGIYAMA H, et al: Phenotypic modulation of the mesangium reflected by contractile proteins in diabetes. Diabetes 45:488-495, 1996
17. RICOTE M, LI AC, WILSON TM, KELLY CJ, et al: The peroxisome proliferator-activated receptor γ is a negative regulator of macrophage activation. Nature 391:79-82, 1998
18. KAWAHITO Y, KONDO M, TUBOUCHI Y, et al: 15 deoxy-12, 14 delta-PGJ2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 106:189-197, 2000
19. TSUBOUCHI Y, SANO H, KAWAHITO Y, et al: Inhibition of human lung cancer cell growth by the peroxisome proliferator activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 270:400-405, 2000
20. MULLER E, SARRAF P, TONTONOZ P, et al: Terminal differentiation of human breast cancer through PPAR γ. Mol Cell 1:465-470, 1998
21. FORMAN BM, TONTONOZ P, CHEN J, et al: 15deoxy-12, 14delta-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ. Cell 83:803-812, 1995
22. ISSHIKI K, HANEDA M, KOYA D, et al: Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 49:1022-1032, 2000
23. LEHMANN JM, LENHARD JM, OLIVER BB, et al: Peroxisome proliferator activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272:3406-3410, 1997
24. WAKISAKA M, SPIRO MJ, SPIRO RG: Synthesis of type IV collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen. Diabetes 43:95-103, 1994
25. ISONO M, CRUZ MC, CHEN S, et al: Extracellular signal-regulated kinase mediates stimulation of TGF-beta 1 and matrix by high glucose in mesangial cells. J Am Soc Nephrol 11:2222-2230, 2000
26. WAKISAKA M, KITAZONO T, KATO M, et al: Sodium-coupled glucose transporter as a functional glucose sensor of retinal microvascular circulation. Circ Res 88:1183-1188, 2001
27. ZHANG B, BERGER J, HU E, et al: Negative regulation of peroxisome proliferator-activated receptor γ gene expression contributes to the antiadipogenic effects of tumor necrosis factor-α. Mol Endoclinol 10:1457-1466, 1996
28. TANAKA T, ITOH H, DOI K, et al: Down regulation of peroxisome proliferator-activated receptor gamma expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia 42:702-10, 1999
29. XING H, NORTHROP JP, GROVE JR, et al: TNFα-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARγ without effect on Pref-1 expression. Endcrinology 138:2776-2783, 1997
30. PERREY S, ISHIBASHI S, YAHAGI N, et al: Thiazolidinedione-and tumor necrosis factor α-induced downregulation of peroxisome proliferator-activated receptorγ mRNA in differentiated 3T3-L1 adipocytes. Metabolism 50:36-40, 2001
31. SARTIPPOUR MR, RENIER G: Differential regulation of macrophage peroxisome-proliferator activated receptor expression by glucose: Role of peroxisome proliferator activated receptors in lipoprotein lipase gene expression. Arter Thromb Vasc Biol 20:104-110, 2000
32. WINSTON BW, LANGE-CARTER CA, GARDNER AM, et al: Tumor necrosis factor alpha rapidly activates the mitogen-activated protein kinase (MAPK) cascade in a MAPK kinase kinase-dependent, c-Raf-1-independent fashion in mouse macrophages. Proc Natl Acad Sci USA 92:1614-1618, 1995
33. HAN J, HAJJAR DD, TAURAS JM, FENG J, et al: Transforming growth factor-beta1 (TGF-beta1) and TGF-beta 2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator activated receptor γ. J Biol Chem 275:1241-1246, 2000
34. HANEDA M, KOYA D, KIKKAWA R: Cellular mechanisms in the development of diabetic nephropathy: Activation of the DAG-PKC-ERK pathway. Am J Kidney Dis 38:8178-181, 2001
35. KING GL, BANSKOTA NK: Mechanisms of diabetic microvascular complications, in Joslin's Diabetes Mellitus, edited by Kahn CR, Weir GC, Philadelphia, Lea & Febiger, 1994, pp 631-647
36. DAVIES GF, KHANDELWAL RL, ROESLER WJ: Troglitazone induces expression of PPAR γ in liver. Mol Cell Biol Res Commun 2:202-208, 1999
37. MIYAHARA T, SCHRUM L, RIPPE R, et al: Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275:35715-35722, 2000
38. ASANO T, WAKISAKA M, YOSHINARI M, et al: Troglitazone enhances glycolysis and improves intracellular glucose metabolism in rat mesangial cells. Metabolism 49:308-313, 2000
39. WILLIAMSON JR, DHANG K, FRANGOS M, et al: Hyperglycemic pseudohypoxia and diabetic complication. Diabetes 42:801-813, 1993
40. GOETZE S, KIM S, XI XP, et al: Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells. J Cardiovasc Phamacol 35:749-757, 2000
41. WILLMER WA, DIXON C, LU L, et al: A cyclopentenone prostaglandin activates mesangial MAP kinase independently of PPARγ. Biochem Biophys Acta 281:57-62, 2001
42. TAKEDA K, ICHIKI T, TOKUNOU T, et al: 15-deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J Biol Chem 276:48950-48955, 2001
43. KITAMURA M, MITARAI T, NAGASAWA R, et al: Differentiated phenotype of glomerular mesangial cells in nodular culture. Am J Physiol 270:F614-622, 1996
44. SEARS IB, MACGINNITIE MA, KOVACS RA: Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: Regulation by peroxisome proliferator-activated receptor gamma. Mol Cell Biol 16:3410-3419, 1996
45. 2+ kinetics and contraction in cultured rat glomerular mesangial cells. Am J Physiol 254:F254-F266, 1988
46. OUARDANI M, TRAVO P, BASTIE MJ, et al: Loss of differences in mesangial cell phenotype between diabetic and normal rats: Role of culture passages. Biol Cell 86:127-133, 1996
47. MALHOTRA A, KANG BP, CHEUNG S, et al: Angiotensin II promotes glucose-induced activation of cardiac protein kinase C isozymes and phosphorylation of troponin I. Diabetes 50:1918-1926, 2001
48. GUAN Y, ZHANG Y, SCHNEIDER A, et al: Peroxisome proliferator-activated receptor-γ activity is associated with renal microvasculature. Am J Physiol 281:F1036-F1046, 2001
49. NAKAMURA Y, OHYA Y, ONAKA U, et al: Inhibitory action of insulin-sensitizing agents on calcium channel in smooth muscle cells from resistance arteries of guinea-pig. Br J Pharmacol 123:675-682, 1998
50. BUCHANAN TA, MEEHAN WP, JENG YY, et al: Blood pressure low-ering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 96:354-360, 1995
51. SUGAWARA A, TAKEUCHI K, URUNO A, et al: Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-γ in vascular smooth muscle cells. Endocrinology 142:3125-3134, 2001
52. WILLIAMS B, SCHRIER RW: Glucose-induced protein kinase C activity regulates arachidonic acid release and eicosanoid production by cultured glomerular mesangial cells. J Clin Invest 92:2889-2896, 1993
53. DUNLOP M, KEOGH R, LARKINS RG: Fibronectin-induced increase in mesangial cell prostaglandin release. Effect of hyperglycemia and PKC inhibition. Diabetes 42:183-190, 1993
54. FOIDART JB, MAHIEU P: Glomerular mesangial cell contractility in vitro is controlled by an angiotensin prostaglandin balance. Mol Cell Endoclin 47:163-173, 1986
55. TOMINAGA T, FUKATA J, NAITO Y, et al: Prostaglandin-dependent in vitro stimulation of adrenocortical steroidogenesis by interleukins. Endocrinology 128:526-531, 1991